Spots Global Cancer Trial Database for The Clinical Markers for PARP Inhibitors-related Efficacy in Ovarian Cancer
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: The Clinical Markers for PARP Inhibitors-related Efficacy in Ovarian Cancer
Official Title: A Real-world Study of Clinical Markers for PARP Inhibitors in Epithelial Ovarian Cancer
Study ID: NCT04582552
Interventions
Study Description
Brief Summary: Epithelial ovarian cancer (EOC) is the most lethal gynecological malignancy. PARP inhibitors(PARPi) are an important progress in EOC treatment. The available evidence suggests that BRCAmt or HRD-positive is an effective biological marker for PARPi. However, in our previous clinical observation, it was found that the tumor burden may be the potential clinical markers PARPi. We intend to develop a real-world study to confirm the potential clinical markers and explore new clinical markers for PARPi.
Detailed Description: This study intends to conduct a systematic real-world study to observe the relationship between the clinical characteristics of EOC patients and the efficacy of PARPi based on our existing research foundation and stratified analyse these correlations by BRCA and HRD status.
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: FEMALE
Healthy Volunteers: No
Locations
Xiaoxiang Chen, MD,PhD, Nanjing, Jiangsu, China
Contact Details
Name: Xiaoxiang Chen, MD,PhD
Affiliation: Jiangsu Cancer Institute & Hospital
Role: STUDY_CHAIR
Name: Jing Ni, MD
Affiliation: Jiangsu Cancer Institute & Hospital
Role: PRINCIPAL_INVESTIGATOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
